Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.46 |
| ▸ | TYR | P14679 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.44 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105825 | 0.87 | ALDH1A1 (0.52) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL11525980 | 0.81 | ALDH1A1 (0.46) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL14030704 | 0.81 | ALDH1A1 (0.52) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL4982793 | 0.81 | CYP2C9 (0.68) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL23387403 | 0.79 | ALOX15 (0.45) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL6130125 | 0.79 | ALOX15 (0.45) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| Hydrogen Sulfide SCHEMBL11348298 | 0.79 | CYP2C9 (0.65) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL12733097 | 0.77 | ALOX15 (0.43) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL8415616 | 0.77 | ALOX15 (0.62) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL25696416 | 0.77 | ALDH1A1 (0.43) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12305082-B2 | Curable-type composition, two-component curable-type composition set, and method of producing adhered product | TOAGOSEI CO., LTD. | 2025-05-20 | — | — | US | disclosed |
| CN-119490388-A | Method for separating and obtaining phenolic substances from phenol-containing coal tar | 煤炭科学技术研究院有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-119431113-A | Method for refining 2,3, 5-tricresyl and 3-methyl-5-ethylphenol from trimethylphenol mixture | 煤炭科学技术研究院有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230002642-A1 | CURABLE COMPOSITION, TWO-LIQUID TYPE CURABLE COMPOSITION SET, AND METHOD FOR MANUFACTURING ADHERED PRODUCT | TOAGOSEI CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
| US-20220380615-A1 | CURABLE COMPOSITION, TWO-LIQUID TYPE CURABLE COMPOSITION SET, AND METHOD FOR MANUFACTURING ADHERED PRODUCT | TOAGOSEI CO., LTD. (JP) | 2022-12-01 | — | — | US | disclosed |
| US-20220282135-A1 | CURABLE-TYPE COMPOSITION, TWO-COMPONENT CURABLE-TYPE COMPOSITION SET, AND METHOD OF PRODUCING ADHERED PRODUCT | TOAGOSEI CO., LTD. (JP) | 2022-09-08 | — | — | US | disclosed |
| US-11358959-B2 | Benzothiophene and benzothiazole compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | ARAXES PHARMA LLC (US) | 2022-03-22 | — | — | US | disclosed |
| US-11059819-B2 | Fused hetero-hetero bicyclic compounds and methods of use thereof | JANSSEN BIOTECH, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2021049588-A1 | CURABLE COMPOSITION, TWO-COMPONENT CURABLE COMPOSITION SET, AND METHOD FOR PRODUCING ADHESIVE | 東亞合成株式会社 | 2021-03-18 | — | — | WO | disclosed |
| WO-2021049589-A1 | CURABLE COMPOSITION, TWO-LIQUID CURABLE COMPOSITION SET, AND METHOD FOR PRODUCING BONDED ARTICLE | 東亞合成株式会社 | 2021-03-18 | — | — | WO | disclosed |
| WO-2021049590-A1 | CURABLE COMPOSITION, TWO-PACK CURABLE COMPOSITION SET AND METHOD FOR PRODUCING BONDED ARTICLE | 東亞合成株式会社 | 2021-03-18 | — | — | WO | disclosed |
| US-20200385364-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2020-12-10 | — | — | US | disclosed |
| WO-2020085335-A1 | PRODUCTION METHOD FOR 2-CYANOACRYLATE COMPOUND AND PRODUCTION METHOD FOR PHOTOCURABLE ADHESIVE COMPOSITION | 東亞合成株式会社 | 2020-04-30 | — | — | WO | disclosed |
| WO-2020085334-A1 | PHOTOCURABLE ADHESIVE COMPOSITION | 東亞合成株式会社 | 2020-04-30 | — | — | WO | disclosed |
| US-20190345158-A1 | FUSED HETERO-HETERO BICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2019-11-14 | — | — | US | disclosed |
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | ALDH1A1 4072/4885ALOX15 4495/4885CYP2C9 3242/4885 |
| US-11059819-B2 | Fused hetero-hetero bicyclic compounds and methods of use thereof | KRAS, NRAS, HRAS | ALDH1A1 4653/4885ALOX15 4120/4885CYP2C9 2581/4885 |
| US-11358959-B2 | Benzothiophene and benzothiazole compounds and methods of use thereof | KRAS, NRAS, RB1 | ALDH1A1 959/4885ALOX15 3387/4885CYP2C9 2850/4885 |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 1402/4885ALOX15 4525/4885CYP2C9 3016/4885 |
| US-20190345158-A1 | FUSED HETERO-HETERO BICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 4653/4885ALOX15 4120/4885CYP2C9 2581/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 4303/4885ALOX15 4579/4885CYP2C9 3239/4885 |
| US-20200385364-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 1468/4885ALOX15 4632/4885CYP2C9 2890/4885 |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | KRAS, NRAS, HRAS | ALDH1A1 1729/4885ALOX15 4640/4885CYP2C9 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.